Responses
Regular and young investigator award abstracts
Clinical trials in progress
323 Systemic administration of ladiratuzumab vedotin alone or in combination with pembrolizumab results in significant immune activation in the tumor microenvironment in metastatic breast cancer patients
Compose a Response to This Article
Other responses
No responses have been published for this article.